Fig. 2From: Resource utilization and costs associated with the addition of an antimuscarinic in patients treated with an alpha-blocker for the treatment of urinary symptoms linked to benign prostatic hyperplasiaDifferences in mean cost after adding an AM agent. Values in Euros (€); AAB:Alpha-blockers; AM: AntimuscarinicsBack to article page